A patient with a penicillin allergy is being considered for a cephalosporin. Which question best determines whether a cephalosporin can be safely prescribed?

A patient with a penicillin allergy is being considered for a cephalosporin. Which question best determines whether a cephalosporin can be safely prescribed?

• A. Have You Ever Taken a Cephalosporin?
• B. What kind of reaction did you have?
• C. How long ago was the reaction?
• D. What form of penicillin did you take?

Answer: (B)

The key idea is that safety of using a cephalosporin in someone with a penicillin allergy hinges on the type of reaction they had to penicillin, not just whether they were allergic in the past. If the penicillin reaction was an immediate IgE-mediated response (like anaphylaxis, hives, or swelling of the face or throat), there’s a meaningful risk of cross-sensitivity to cephalosporins, especially certain generations with similar side chains, so the clinician must weigh risks, choose a cephalosporin with a different side chain if used, or consider alternatives with careful monitoring. If the penicillin reaction was a non–IgE-mediated or mild delayed rash, the cross-reactivity risk is much lower, and a cephalosporin can often be used more safely. Thus, asking what kind of reaction the patient had directly informs the likelihood of cross-sensitivity and guides the safest prescribing choice. The other questions provide useful information but are less predictive of cross-reactivity: whether they’ve ever taken a cephalosporin doesn’t tell you the penicillin-related risk, how long ago the reaction occurred doesn’t change the immunologic likelihood, and which penicillin was taken is less definitive than the reaction type in determining safety.

The key idea is that safety of using a cephalosporin in someone with a penicillin allergy hinges on the type of reaction they had to penicillin, not just whether they were allergic in the past. If the penicillin reaction was an immediate IgE-mediated response (like anaphylaxis, hives, or swelling of the face or throat), there’s a meaningful risk of cross-sensitivity to cephalosporins, especially certain generations with similar side chains, so the clinician must weigh risks, choose a cephalosporin with a different side chain if used, or consider alternatives with careful monitoring. If the penicillin reaction was a non–IgE-mediated or mild delayed rash, the cross-reactivity risk is much lower, and a cephalosporin can often be used more safely.

Thus, asking what kind of reaction the patient had directly informs the likelihood of cross-sensitivity and guides the safest prescribing choice. The other questions provide useful information but are less predictive of cross-reactivity: whether they’ve ever taken a cephalosporin doesn’t tell you the penicillin-related risk, how long ago the reaction occurred doesn’t change the immunologic likelihood, and which penicillin was taken is less definitive than the reaction type in determining safety.